August 19, 2020

Sofosbuvir and Daclatasvir Compared with Standard of Care in the Treatment of Patients Admitted to Hospital with Moderate or Severe Coronavirus Infection (COVID-19): A Randomized Controlled Trial

Category: Article Summary

Topic: Testing and Treatment

• In an open-label, multicenter, randomized clinical trial in adults with moderate or severe COVID-19 admitted to four university hospitals in Iran, the addition of drugs used to treat hepatitis C virus, sofosbuvir and daclatasvir, to standard care (n=33) significantly reduced the duration of hospital stay compared with standard care alone (n=33). Cumulative incidence of hospital discharge was significantly higher in the treatment versus the control arm. Although fewer deaths were observed in the treatment arm, the difference was not statistically significant. 

Sadeghi et al. (Aug 19, 2020). Sofosbuvir and Daclatasvir Compared with Standard of Care in the Treatment of Patients Admitted to Hospital with Moderate or Severe Coronavirus Infection (COVID-19): A Randomized Controlled Trial. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaa334